Clinical Scorecard: Evaluation of Practical Monitoring Approaches for Patients Receiving Systemic Treatment for Brain Metastases
At a Glance
Category
Detail
Condition
Brain metastases treated with systemic therapy
Key Mechanisms
Use of CNS-penetrating systemic therapies as alternatives to radiotherapy
Target Population
Patients with active brain metastases receiving systemic therapy alone
Care Setting
Oncology outpatient setting with MRI surveillance
Key Highlights
Systemic therapies with CNS penetration are increasingly used upfront for brain metastases, sometimes outside established guidelines.
Surveillance MRI timing varied widely; median times to first three MRIs were 45, 95, and 180 days respectively.
Many patients delayed radiation therapy for over one year with infrequent neurological adverse events during systemic treatment.
Guideline-Based Recommendations
Diagnosis
Use MRI surveillance to monitor intracranial disease progression during systemic therapy.
Management
Consider CNS-penetrating systemic therapies supported by 2021 ASCO-SNO-ASTRO guidelines for selected patients.
Defer upfront radiation therapy in appropriate cases to reduce treatment-related toxicity.
Monitoring & Follow-up
Perform surveillance MRIs at intervals similar to those observed (approximately every 1.5 to 3 months initially).
Monitor for local and distant intracranial progression using MRI.
Risks
Potential for intracranial progression requiring delayed radiation therapy.
Neurological adverse events such as seizures are infrequent but possible.
Patient & Prescribing Data
33 patients treated with systemic therapy alone for active brain metastases from 2021 to 2024
14 patients received systemic therapies aligned with 2021 guidelines; progression rates and radiation incidence were similar between guideline and non-guideline groups.
Clinical Best Practices
Stratify systemic therapy choice based on molecular markers and guideline-supported drug-disease combinations.
Schedule regular MRI surveillance to detect intracranial progression early.
Balance delaying radiation therapy against risk of progression and neurological events.
Document and monitor neurological adverse events during systemic therapy.
